BBIO BridgeBio Pharma Inc

Price (delayed)

$25.24

Market cap

$4.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.95

Enterprise value

$5.79B

BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in ...

Highlights
The gross profit has plunged by 91% YoY
BridgeBio Pharma's revenue has plunged by 88% YoY

Key stats

What are the main financial stats of BBIO
Market
Shares outstanding
175.83M
Market cap
$4.44B
Enterprise value
$5.79B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
441.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
621.87
Earnings
Revenue
$9.3M
EBIT
-$561.91M
EBITDA
-$551.39M
Free cash flow
-$529.03M
Per share
EPS
-$3.95
Free cash flow per share
-$3.25
Book value per share
-$7.78
Revenue per share
$0.06
TBVPS
$3.19
Balance sheet
Total assets
$546.38M
Total liabilities
$1.89B
Debt
$1.74B
Equity
-$1.35B
Working capital
$333.75M
Liquidity
Debt to equity
-1.28
Current ratio
3.32
Quick ratio
3.15
Net debt/EBITDA
-2.44
Margins
EBITDA margin
-5,927%
Gross margin
73.7%
Net margin
-6,913.9%
Operating margin
-6,528.8%
Efficiency
Return on assets
-110.4%
Return on equity
N/A
Return on invested capital
-32%
Return on capital employed
-139.6%
Return on sales
-6,040.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
-2.06%
1 week
-11.22%
1 month
-8.42%
1 year
71.23%
YTD
-37.48%
QTD
-18.37%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$9.3M
Gross profit
$6.86M
Operating income
-$607.37M
Net income
-$643.2M
Gross margin
73.7%
Net margin
-6,913.9%
The gross profit has plunged by 91% YoY
BridgeBio Pharma's revenue has plunged by 88% YoY
BBIO's net income is down by 34% year-on-year and by 5% since the previous quarter
BridgeBio Pharma's gross margin has decreased by 23% YoY

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
441.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
621.87
BBIO's EPS is down by 21% year-on-year
BBIO's equity is down by 12% since the previous quarter and by 8% year-on-year
BridgeBio Pharma's revenue has plunged by 88% YoY
The stock's price to sales (P/S) is 72% more than its 5-year quarterly average of 256.1 and 5% more than its last 4 quarters average of 420.6

Efficiency

How efficient is BridgeBio Pharma business performance
The ROA has plunged by 74% YoY and by 8% from the previous quarter
The ROIC has plunged by 51% YoY and by 7% from the previous quarter
BBIO's ROS is down by 7% since the previous quarter

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 71% smaller than its total liabilities
BridgeBio Pharma's quick ratio has decreased by 41% from the previous quarter and by 27% YoY
The current ratio has decreased by 40% QoQ and by 27% YoY
BBIO's equity is down by 12% since the previous quarter and by 8% year-on-year
BBIO's debt to equity is up by 11% since the previous quarter and by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.